Table 2.
Cox Regression Analysis of Risk Factors for Mortality in CRAB-BSI
| Variable, n (%) | Death | Survivors | P | Multivariate Analysis | ||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | ||||
| Male | 37 (74.0) | 50 (64.1) | 0.093 | 1.591 | 0.807–3.137 | 0.180 |
| Age ≥65 years | 18 (36.0) | 28 (35.9) | 0.689 | |||
| Hospital-acquired infection | 41 (82.0) | 63 (80.8) | 0.904 | |||
| Source of infection of the respiratory tract | 26 (52.0) | 42 (53.8) | 0.090 | 1.318 | 0.716–2.429 | 0.375 |
| ICU admission | 48 (96.0) | 72 (92.3) | 0.230 | |||
| Septic shock | 44 (88.0) | 45 (57.7) | 0.001 | 3.664 | 1.537–8.736 | 0.003 |
| Comorbidities | ||||||
| Hypertension | 17 (34.0) | 33 (42.3) | 0.377 | |||
| Diabetes | 10 (20.0) | 21 (26.9) | 0.848 | |||
| Cardiovascular disease | 19 (38.0) | 17 (21.8) | 0.033 | 1.397 | 0.752–2.594 | 0.291 |
| Respiratory disease | 31 (62.0) | 41 (52.6) | 0.209 | |||
| Hepatobiliary disease | 12 (24.0) | 23 (29.5) | 0.138 | |||
| Kidney Disease | 15 (30.0) | 28 (35.9) | 0.534 | |||
| Invasive operation | ||||||
| Arteriovenous cannulation | 44 (88.0) | 71 (91.0) | 0.164 | |||
| Endotracheal intubation | 47 (94.0) | 66 (84.6) | 0.207 | |||
| Urinary catheter | 31 (62.0) | 50 (64.1) | 0.633 | |||
| Antimicrobial use prior to BSI | ||||||
| Beta-lactam combinations | 27 (54.0) | 32 (41.0) | 0.242 | |||
| Carbapenem | 42 (84.0) | 64 (82.1) | 0.716 | |||
| ≥2 antimicrobial drugs | 41 (82.0) | 68 (87.2) | 0.319 | |||
| Targeted antimicrobial treatment | ||||||
| Tigecycline | 8 (16.0) | 23 (29.5) | 0.097 | 0.549 | 0.255–1.183 | 0.126 |
| Polymyxin | 8 (16.0) | 13 (16.7) | 0.810 | |||
| Tigecycline and polymyxin combination | 17 (34.0) | 20 (25.6) | 0.376 | |||
Abbreviations: CRAB-BSI, carbapenem-resistant Acinetobacter baumannii bloodstream infection; HR, hazard ratio; CI, confidence interval.